In preclinical studies, VT1021 inhibited tumor growth via TSP-1 stimulation that resulted in the reprogramming of the TME from immunosuppressive and tumor-promoting to immune active and tumor-inhibiting1,10,22. Here, THBS1 is linked to neoplasm.